Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
977 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (401)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07692360 | Salivary IL-6 and Interleukin Gene Polymorphisms in Oral Squamous Cell Carcinoma(IL6-OSCC) | not yet recruiting | — | 38 | University of PaviaOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04291105 | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | active not recruiting | Phase 2 | 87 | Vyriad, Inc.INDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT06288191 | Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma | recruiting | Phase 2 | 20 | Melanoma Institute AustraliaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06797986 | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. | recruiting | Phase 1 / Phase 2 | 37 | Cellid Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07567235 | Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | not yet recruiting | Phase 1 / Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT06165380 | Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 43 | Li ZhangOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06403436 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors(TT-CSP-001) | completed | Phase 1 | 45 | TOLREMO therapeutics AGINDUSTRY | 3 | Jul 7, 2026 | clinicaltrials |
| NCT06996249 | Prospective Data Collection Initiative on Thoracic Malignancies(DuTOC) | recruiting | — | 12,000 | Dutch Society of Physicians for Pulmonology and TuberculosisOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07149207 | Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors | recruiting | Phase 2 | 30 | Medical University of South CarolinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07224750 | A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer(MiGIC) | recruiting | — | 1,000 | City of Hope Medical CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07403136 | Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC | recruiting | Phase 2 | 104 | Fudan UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07460765 | Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) | recruiting | Phase 1 | 40 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07686575 | Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma | recruiting | — | 20 | Zhujiang HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07688291 | A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy | not yet recruiting | Phase 2 | 40 | Beijing GoBroad HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | recruiting | Phase 1 | 1,006 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 6, 2026 | clinicaltrials |
| NCT04609566 | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | completed | Phase 2 | 161 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04831320 | Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | active not recruiting | Phase 2 | 46 | Washington University School of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07136545 | A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial) | recruiting | Phase 1 / Phase 2 | 50 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683507 | Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | Feng LiuOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT03952585 | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | active not recruiting | Phase 2 / Phase 3 | 384 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT05070403 | Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma | active not recruiting | Phase 2 | 35 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05522881 | The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan | recruiting | — | 410 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06919666 | NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 29 | University of Colorado, DenverOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07680088 | Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer | not yet recruiting | Phase 2 | 17 | University of Texas Southwestern Medical CenterOTHER | 0 | Jul 2, 2026 | clinicaltrials |
| NCT07682285 | Taiwanese Green Propolis for Lipid Profiles, Fatigue, and Quality of Life in Oral Cavity Cancer Survivors(TGP-OCS) | completed | N/A | 25 | Taipei Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07682376 | Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 96 | Harbin Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT01772706 | Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer(LaserMucite) | completed | N/A | 97 | Institut Cancerologie de l'OuestOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06364384 | Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma | recruiting | Phase 2 | 20 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07010120 | A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 29 | West China HospitalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07213934 | Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 40 | University of CincinnatiOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07667296 | APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 826 | Aveta Biomics, Inc.INDUSTRY | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07678580 | Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 50 | Tang-Du HospitalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07679997 | Trilaciclib Combined With Immunochemotherapy for R/M HNSCC | not yet recruiting | Phase 2 | 32 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07040956 | A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. | completed | Phase 2 | 98 | West China HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04566432 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients | completed | — | 252 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05520099 | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)(ELEPHAS-02) | active not recruiting | — | 416 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT07674706 | Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers | not yet recruiting | N/A | 50 | National University Hospital, SingaporeOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06366451 | PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC | completed | Early Phase 1 | 17 | Presage BiosciencesINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07094685 | Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer(SENIOR-HN) | recruiting | Phase 2 | 28 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07670403 | Digital Phenotyping of Psychological Distress in Skin Cancer Patients(DP-SKIN) | completed | — | 500 | West China HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07671573 | Integrated Early-CARE for Head & Neck Cancer.(i-CARE-HN) | not yet recruiting | N/A | 64 | Portuguese Oncology Institute, CoimbraOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03139058 | Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck(fibr'HOM) | terminated | N/A | 2 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04862650 | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 2 | 46 | Marcelo BonomiOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04975152 | Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma | recruiting | Phase 1 | 36 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05050162 | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer | suspended | Phase 2 / Phase 3 | 1,714 | NRG OncologyOTHER | 5 | Jun 25, 2026 | clinicaltrials |
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Ankyra Therapeutics, IncINDUSTRY | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07215988 | Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study | recruiting | — | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 9, 2026source: clinicaltrials